Last reviewed · How we verify
Familial hypercholesterolemia - homozygous
Approved treatments
- Ezetrol · NVP Healthcare
- Kynamro · Kastle Theraps Llc
- Juxtapid · Chiesi
Juxtapid works by blocking the protein that helps transport cholesterol into the bloodstream. - Zetia · Merck & Co.
Zetia works by blocking the absorption of cholesterol in the small intestine. - Lipitor · Pfizer Inc.
Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - Zocor · Merck & Co.
- Crestor · AstraZeneca
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor. - Lipitor · Pfizer
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis. - Repatha · Repatha
Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL.
Clinical guidelines
- FDA label — adj
As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). - FDA label — adj
As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). - FDA label — adj
As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Familial hypercholesterolemia - homozygous patent landscape — cliff calendar, originator estates, attackable patents
- Familial hypercholesterolemia - homozygous treatment landscape brief
- Familial hypercholesterolemia - homozygous treatment updates RSS
Frequently asked questions about Familial hypercholesterolemia - homozygous
What drugs treat Familial hypercholesterolemia - homozygous?
Tracked treatments include Ezetrol, Kynamro, Juxtapid, Zetia, Lipitor, Zocor, Crestor, Repatha.
What is the treatment for Familial hypercholesterolemia - homozygous?
Standard treatment for Familial hypercholesterolemia - homozygous includes Ezetrol, Kynamro, Juxtapid, Zetia, Lipitor. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Familial hypercholesterolemia - homozygous?
FDA label publishes guidelines for Familial hypercholesterolemia - homozygous. 3 guideline references tracked.
Related
- Treatment landscape: Familial hypercholesterolemia - homozygous patent cliff · Familial hypercholesterolemia - homozygous CI report
- Treatment: Ezetrol · NVP Healthcare
- Treatment: Kynamro · Kastle Theraps Llc
- Treatment: Juxtapid · Chiesi
- Treatment: Zetia · Merck & Co.
- Treatment: Lipitor · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing